Quality of life in elderly breast cancer patients with localized disease receiving endocrine treatment: a prospective study

Purpose In this paper we study the quality of life (QoL) of elderly breast cancer patients receiving endocrine treatment (ET). More QoL data on elderly patients treated with ET are needed. Our aims are to study QoL in early-stage breast cancer patients throughout the treatment period and compare the...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2019-09, Vol.21 (9), p.1231-1239
Main Authors: Arraras, J. I., Illarramendi, J. J., Manterola, A., Asin, G., Salgado, E., Arrondo, P., Dominguez, M. A., Arrazubi, V., Martinez, E., Viudez, A., de la Cruz, S., Vera, R.
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Agents, Hormonal - therapeutic use
Breast Neoplasms - drug therapy
Female
Follow-Up Studies
Humans
Medicine
Medicine & Public Health
Oncology
Prognosis
Prospective Studies
Quality of Life
Research Article
Surveys and Questionnaires
Tamoxifen - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose In this paper we study the quality of life (QoL) of elderly breast cancer patients receiving endocrine treatment (ET). More QoL data on elderly patients treated with ET are needed. Our aims are to study QoL in early-stage breast cancer patients throughout the treatment period and compare the QoL of ET groups. Methods 148 patients > 65 years who began ET with either tamoxifen or aromatase inhibitor (AI) completed the EORTC QLQ-C30 and QLQ-BR23 and the Interview for Deterioration in Daily Living Activities in Dementia (IDDD) questionnaires three times over 3 years of ET. Linear mixed-effect models were used to evaluate longitudinal QoL changes. ET group comparisons were conducted after 3 years of treatment via ANCOVA adjusted by basal QoL. Results QoL scores were high (> 80/100 points) in most QoL areas, with moderate limitations (> 30) in sexual functioning and enjoyment and in future perspective. After 3 years of ET, four QoL areas improved (
ISSN:1699-048X
1699-3055
DOI:10.1007/s12094-019-02048-4